Furosemide
- Generic Name
- Furosemide
- Brand Names
- Furoscix, Lasix
- Drug Type
- Small Molecule
- Chemical Formula
- C12H11ClN2O5S
- CAS Number
- 54-31-9
- Unique Ingredient Identifier
- 7LXU5N7ZO5
- Background
Furosemide is a potent loop diuretic that acts on the kidneys to ultimately increase water loss from the body. It is an anthranilic acid derivative. Furosemide is used for edema secondary to various clinical conditions, such as congestive heart failure exacerbation, liver failure, renal failure, and high blood pressure. It mainly works by inhibiting electrol...
- Indication
Furosemide is indicated for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome, in adults and pediatric patients.
...
- Associated Conditions
- Acute Pulmonary Edema, Ascites, Body Fluid Retention, Edema, Hypertension, Mild to Moderate Hypertension, Chest congestion
- Associated Therapies
- -
A Study to Assess the Effects of Savolitinib on the Pharmacokinetics of Digoxin, Rosuvastatin, Metformin, and Furosemide in Healthy Male Subjects
- Conditions
- Interventions
- First Posted Date
- 2023-03-14
- Last Posted Date
- 2023-07-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 6
- Registration Number
- NCT05768360
- Locations
- 🇩🇪
Research Site, Berlin, Germany
A Study to Compare How Different Medicines (Rosuvastatin, Digoxin, Metformin, and Furosemide) Are Handled by the Body of Healthy People and People With Liver Cirrhosis
- Conditions
- Interventions
- First Posted Date
- 2023-02-23
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 30
- Registration Number
- NCT05741372
- Locations
- 🇩🇪
CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany
Intra-operative Loop Diuretics to Improve Same-day Discharge Rates After HoLEP
- Conditions
- Interventions
- First Posted Date
- 2022-11-17
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 138
- Registration Number
- NCT05620784
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
Efficacy and Safety Evaluation of Tolvaptan in the Treatment of Patients With RHF Caused by PAH
- Conditions
- Interventions
- First Posted Date
- 2022-10-06
- Last Posted Date
- 2022-10-06
- Target Recruit Count
- 100
- Registration Number
- NCT05569655
- Locations
- 🇨🇳
center of pulmonary vascular disease, Fuwai hospital, Beijing, China
Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma
- Conditions
- Interventions
- First Posted Date
- 2022-07-22
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 21
- Registration Number
- NCT05470283
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Outpatient Recovery From Acute Kidney Injury Requiring Dialysis
- Conditions
- Interventions
- First Posted Date
- 2021-12-15
- Last Posted Date
- 2023-05-12
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 1
- Registration Number
- NCT05158153
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
Furosemide Use to Fill the Bladder of Pediatric Females Awaiting Pelvic Ultrasound
- First Posted Date
- 2021-10-28
- Last Posted Date
- 2024-05-31
- Lead Sponsor
- Connecticut Children's Medical Center
- Target Recruit Count
- 42
- Registration Number
- NCT05098366
- Locations
- 🇺🇸
Connecticut Children's Medical Center, Hartford, Connecticut, United States
Torsemide Comparison With Furosemide for Management of Patients With Stable Heart Failure
- First Posted Date
- 2021-10-26
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Yale University
- Target Recruit Count
- 47
- Registration Number
- NCT05093621
- Locations
- 🇺🇸
Yale University, New Haven, Connecticut, United States
Amiloride in Nephrotic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2021-10-15
- Last Posted Date
- 2023-07-05
- Lead Sponsor
- University Hospital Tuebingen
- Target Recruit Count
- 20
- Registration Number
- NCT05079789
- Locations
- 🇩🇪
University Hospital Tuebingen, Tuebingen, Baden-Wuerttemberg, Germany
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986308 in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2021-02-21
- Last Posted Date
- 2022-04-27
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 46
- Registration Number
- NCT04763226
- Locations
- 🇺🇸
Local Institution - 0001, Lenexa, Kansas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.